SCHEMBL13181773

SCHEMBL13181773

CC(C)(C)OC(=O)NCc1cccc(/C=N/O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLS O94925 3/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
BRD4 O60885 3/20 0.44
KDM4A O75164 1/20 0.43
NAMPT P43490 2/20 0.43
CREBBP Q92793 1/20 0.43
BRD9 Q9H8M2 1/20 0.42
BAZ2B Q9UIF8 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42
KDM4E B2RXH2 2/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC1 Q13547 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12206558 1.00 GLS (0.47) GLSRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2636114 0.88 NQO2 (0.46) GLSRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL209838 0.85 GLS (0.52) GLSBRD4KDM4ANAMPTCREBBP
SCHEMBL29952891 0.85 GLS (0.52) GLSBRD4KDM4ANAMPTCREBBP
SCHEMBL3862899 0.84 LMNA (0.42) GLSSMN1; SMN2KDM4EALDH1A1PKM
SCHEMBL3862895 0.84 LMNA (0.42) GLSSMN1; SMN2KDM4EALDH1A1PKM
SCHEMBL3243218 0.84 NAMPT (0.49) RAB9ANPC1MAPTSMN1; SMN2NAMPT
SCHEMBL3243222 0.84 NAMPT (0.49) RAB9ANPC1MAPTSMN1; SMN2NAMPT
SCHEMBL25370290 0.82 GLS (0.47) GLSBRD4KDM4ANAMPTCREBBP
SCHEMBL8985043 0.82 MMP1 (0.51) GLSSMN1; SMN2BRD4KDM4ACREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450459-B2 IL-21 derivatives and variants NOVO NORDISK A/S (DK) 2013-05-28 US disclosed
US-8450459-B2 IL-21 derivatives and variants NOVO NORDISK A/S (DK) 2013-05-28 US disclosed
EP-1673387-B1 IL-21 DERIVATIVES NOVO NORDISK AS (DK) 2010-09-15 EP disclosed
US-20090253864-A1 IL-21 Derivatives and Variants NOVO NORDISK A/S (DK) 2009-10-08 US disclosed
US-20090253864-A1 IL-21 Derivatives and Variants NOVO NORDISK A/S (DK) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253864-A1 IL-21 Derivatives and Variants IL2, IL15, IL23R GLS 1995/4885RAB9A 1558/4885NPC1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.